New self-injected drug could reduce migraines

Migraines affect millions of people around the world.

Now, scientists have developed a drug, self-injected, that reduces the number of headaches they experience.

Trial tests show the drug prevents pain signals in the brain and decrease amount of migraine episodes, the Daily Mail reported.

Out of the 250 people treated with erenumab, it halved the amount of headaches in almost 30% of the participants.

"The people we included in our study were considered more difficult to treat, meaning that up to four other preventative treatments hadn't worked for them," study leader Dr Uwe Reuter, from The Charite-University Medicine Berlin in Germany, told the Daily Mail.

Adding, "Our study found that erenumab reduced the average number of monthly migraine headaches by more than 50 per cent for nearly a third of study participants."

Researchers are hopeful this could help improve the quality of life for people battling this condition.

"There has been no real advancement in migraine treatment for the past 20 years and we're proud to be breaking new ground in neurology for the millions of people in the UK living with the painful and disruptive symptoms of migraine," Dr Mark Toms, chief scientific officer at Novartis UK, told the Daily Mail.